Latest filing published 14 Jun 2024 for Neumora Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
David Piacquad: trading record in brief
David Piacquad files at Amgen Inc under the title SVP, Business Development: 46 of the 47 filings come from Amgen, the last one from Neumora Therapeutics, Inc., where David Piacquad is a director. They are published between March 4, 2016 and June 14, 2024.
The record is almost entirely made of share grants: 42, with 4 option exercises and a single sale of EUR 1,936,022, on February 6, 2020 at Amgen. No purchase is recorded.
Activity was continuous from 2016 to 2021, with a maximum of 10 filings in 2018 and 2019, 7 in 2017 and 2020, and 6 in 2016 and 2021. The record then jumps to 2024, with a single filing, which does not fall in the last twelve months. The median publication delay is 2 days across the 47 filings, and Amgen Inc is by far the main issuer.
The count of trades by Piacquad within 30 days of a colleague at Amgen Inc is 1. Also in the same direction. Colleague: R. Sanders Williams.
Companies and markets linked to David Piacquad
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 20,100 shares0Common StockSEC:0001610717-24-000337:0
- 220 shares@ US$239.640.4% of flowCommon StockSEC:0001127602-21-015364:2
- 139 shares@ US$239.640.3% of flowCommon StockSEC:0001127602-21-015364:1
- 709 shares0Common StockSEC:0001127602-21-015364:0
- 128 shares@ US$255.520.3% of flowCommon StockSEC:0001127602-21-014605:0
- 991 shares@ US$244.422.0% of flowCommon StockSEC:0001127602-21-011714:0
- 2,648 shares0Common StockSEC:0001127602-21-009482:0
- 1,269 shares0Common StockSEC:0001127602-20-015864:0
- 123 shares@ US$239.220.5% of flowCommon StockSEC:0001127602-20-015551:0
- 136 shares@ US$230.980.6% of flowCommon StockSEC:0001127602-20-015551:1
- 116 shares@ US$236.280.5% of flowCommon StockSEC:0001127602-20-014701:0
- 1,591 shares@ US$198.765.9% of flowCommon StockSEC:0001127602-20-011869:0
- 3,711 shares0Common StockSEC:0001127602-20-009711:0
- 9,264 shares@ US$229.9338.0% of flowCommon StockSEC:0001127602-20-004438:0
- 2,875 shares@ US$162.606.5% of flowCommon StockSEC:0001127602-19-034963:0
- 2,425 shares@ US$235.998.0% of flowCommon StockSEC:0001127602-19-034963:1
- 5,749 shares@ US$156.3512.6% of flowCommon StockSEC:0001127602-19-033442:0
- 4,870 shares@ US$224.5015.4% of flowCommon StockSEC:0001127602-19-033442:1
- 1,691 shares0Common StockSEC:0001127602-19-017652:1
- 182 shares@ US$176.500.3% of flowCommon StockSEC:0001127602-19-017652:0
- 171 shares@ US$179.320.3% of flowCommon StockSEC:0001127602-19-017355:0
- 1,509 shares@ US$191.893.0% of flowCommon StockSEC:0001127602-19-013164:0
- 3,676 shares0Common StockSEC:0001127602-19-010658:0
- 162 shares@ US$192.110.3% of flowCommon StockSEC:0001127602-19-003512:0
- 6,500 shares@ US$54.693.5% of flowCommon StockSEC:0001127602-18-035030:0
25 of 59 declarations
